We are monitoring the impact of COVID-19 on Cancer Metabolism Based Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 7866
Share on
Share on

Global Cancer Metabolism Based Therapeutics Market Size, Share, Trends and Growth Analysis Report – Segmented By Therapy, Drug Type, Indication and Region - Industry Forecast (2020 to 2025)

Pulished: February, 2020
ID: 7866
Pages: 175

Cancer Metabolism Based Therapeutics Market Size

The size of the Global Cancer Metabolism Based Therapeutics market is set to grow at a brisk pace during the forecast period.

The hike in this market is driven by several factors, some of them include an increase in the number of people who are diagnosed with cancer every year, smoking tobacco, exposing the body to different types of radiations, heredity, chemicals. Introducing new ways of treating cancers also increasing the market share. The high cost of treatment may drag back the market value in some of the developing countries. Around 3% of the cancer cases and 7% of cancer-related deaths in the U.S. are attributed to pancreatic cancer.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2019 to 2025

Base Year

2019

Forecast Period

2020 to 2025

Segments Covered

By Drug Type, Therapy, Indication and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

AstraZeneca, Novartis, Celgene, Rafael Pharmaceuticals, Cornerstone Pharmaceuticals, Polaris Group, Agios Pharmaceuticals, Taiho Pharmaceuticals, 3-V biosciences, Calithera Biosciences, and BERG Health.

 

This research report on the Global Cancer Metabolism Based Therapeutics Market segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2025.

Cancer Metabolism Based Therapeutics Market Analysis – By Therapy:

  • Biological Drug Therapies  
  • Targeted Drug Therapies  

Cancer Metabolism Based Therapeutics Market Analysis – By Drug Type:

  • Enasidenib              
  • CPI-613     
  • Other Drugs       

On the basis of drug type, the CPI-613 was introduced recently in 2018 which is considered as the best drug to treat pancreatic cancer. Enasidenib also got its importance in treating pancreatic cancer. According to a report from the American Cancer Society in 2018, 53 thousand people were diagnosed with pancreatic cancer and around 43 thousand of them are experiencing a threat to their lives.

Cancer Metabolism Based Therapeutics Market Analysis – By Indication:

  • Melanoma              
  • Myelodyspalstic Syndrome (MDS)
  • Acute Myeloid Leukemia (AML)    
  • Metastatic Renal Cell Carcinoma    
  • Others      

Around twenty-one thousand cases of Acute Myeloid Leukemia attacks were reported by the American Cancer Society in 2018, out of which 50% are experiencing the terminal stage. Many non-profit organizations came into the picture to help people and increased awareness about the symptoms and treatment process of pancreatic cancer which is helping the market to increase its size.

Regional Analysis:

As the number of people suffering from pancreatic cancer is high in North America, the North America Cancer Metabolism Based Therapeutics Market is dominating the Global Market. As there are increasing cases of cancer every year in developing countries like India and China, the potential for market expansion is high in these countries.

List of key market participants leading the Global Cancer Metabolism Based Therapeutics Market profiled in this report are:

  1. AstraZeneca
  2. Novartis
  3. Celgene
  4. Rafael Pharmaceuticals
  5. Cornerstone Pharmaceuticals
  6. Polaris Group
  7. Agios Pharmaceuticals
  8. Taiho Pharmaceuticals
  9. 3-V biosciences
  10. Calithera Biosciences
  11. BERG Health

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapy                       

                                5.1.1 Introduction           

                                5.1.2 Biological Drug Therapies  

                                5.1.3 Targeted Drug Therapies  

                                5.1.4  Y-o-Y Growth Analysis, By Therapy              

                                5.1.5  Market Attractiveness Analysis, By Therapy            

                                5.1.6  Market Share Analysis, By Therapy             

                5.2 Drug Type                   

                                5.2.1 Introduction           

                                5.2.2 Enasidenib              

                                5.2.3 CPI-613     

                                5.2.4 Other Drugs            

                                5.2.5 Y-o-Y Growth Analysis, By Drug Type           

                                5.2.6 Market Attractiveness Analysis, By Drug Type         

                                5.2.7 Market Share Analysis, By Drug Type          

                5.3 Indication                    

                                5.3.1 Introduction           

                                5.3.2 Melanoma              

                                5.3.3 Myelodyspalstic Syndrome (MDS)

                                5.3.4 Acute Myeloid Leukemia (AML)    

                                5.3.5 Metastatic Renal Cell Carcinoma    

                                5.3.6 Others      

                                5.3.7 Y-o-Y Growth Analysis, By Indication           

                                5.3.8 Market Attractiveness Analysis, By Indication         

                                5.3.9 Market Share Analysis, By Indication           

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Therapy

                                                6.1.3.3 By Drug Type

                                                6.1.3.4 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Therapy

                                                6.1.4.3 By Drug Type

                                                6.1.4.4 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Therapy

                                                6.1.5.3 By Drug Type

                                                6.1.5.4 By Indication

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 AstraZeneca                               

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novartis                       

                8.3 Celgene                       

                8.4 Rafael Pharmaceuticals                         

                8.5 Cornerstone Pharmaceuticals                            

                8.6 Polaris Group                             

                8.7 Agios Pharmaceuticals                           

                8.8 Taiho Pharmaceuticals                           

                8.9 3-V Biosciences                         

                8.10 Calithera Biosciences                           

                8.11 BERG Health                            

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Therapy, by  Drug type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

Request Sample Market Brochure to avail List of Tables and Figures of the report.

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample